3.0.0 2362 2025-04-21T12:24:17Z 2025-04-21T12:24:17Z Senate S S 2023-07-18 118 sshr00 Health, Education, Labor, and Pensions Committee Senate Standing Referred To 2023-07-18T23:01:36Z 118 2333 S 2023-09-06 Placed on Senate Legislative Calendar under General Orders. Calendar No. 202. Related bill CRS 2023-07-18 sshr00 Health, Education, Labor, and Pensions Committee Senate Read twice and referred to the Committee on Health, Education, Labor, and Pensions. IntroReferral 2023-07-18 Introduced in Senate IntroReferral 10000 9 Library of Congress K000367 Sen. Klobuchar, Amy [D-MN] Amy Klobuchar D MN N C001035 Sen. Collins, Susan M. [R-ME] Susan Collins R ME M. 2023-07-18 True S001203 Sen. Smith, Tina [D-MN] Tina Smith D MN 2023-07-18 True M001153 Sen. Murkowski, Lisa [R-AK] Lisa Murkowski R AK 2023-07-18 True W000817 Sen. Warren, Elizabeth [D-MA] Elizabeth Warren D MA A. 2023-07-18 True P000595 Sen. Peters, Gary C. [D-MI] Gary Peters D MI 2024-12-18 False W000779 Sen. Wyden, Ron [D-OR] Ron Wyden D OR 2024-12-18 False Health Health 2023-08-17T16:15:22Z

00 2023-07-18 Introduced in Senate 2024-01-17T17:39:53Z <p><b>Drug Shortage Prevention Act of 2023</b></p> <p>This bill requires drug manufacturers to notify the Food and Drug Administration (FDA) if there is an increased demand, export restriction, or other circumstance that may result in a shortage of certain critical drugs. </p> <p>Currently, drug manufacturers are required to notify the FDA in the event of a discontinuation or interruption in the supply of prescription drugs that are life-supporting, life-sustaining, or used for a debilitating disease or condition, including those used in medical emergencies, surgeries, or public health emergencies.</p> <p>The bill requires drug manufacturers to also notify the FDA if there is an increased demand, export restriction, or other circumstance that may result in a meaningful shortfall or delay in meeting the demand for such drugs. Manufacturers must notify the FDA as soon as possible but no later than 10 days after the onset of the relevant circumstance. The notice must include the reasons for the increased demand, the expected duration, and any other information the FDA requires. The bill's requirements apply to both prescription and nonprescription drugs. </p> <p>Drug manufacturers must also report twice a year (rather than annually) information on the quantities of drugs produced; manufacturers must also provide the names of the suppliers of corresponding active ingredients.</p>

Display Title 45 2024-12-19T12:03:15Z Official Title as Introduced 6 2024-12-19T11:56:38Z Introduced in Senate IS Short Title(s) as Introduced 101 2024-05-24T13:37:49Z Introduced in Senate IS Introduced in Senate 2023-07-18T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-118s2362is/xml/BILLS-118s2362is.xml 2023-07-18 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.